コロラド州における多発性骨髄腫の臨床試験
コロラド州内の拠点で、多発性骨髄腫に関する37件の研究が参加者を募集しています。
コロラド州内の都市
公式研究テキスト（英語）
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07589634A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Local Institution - 0381, Aurora
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05519085A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Colorado Blood Cancer Institute /ID# 280275, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Denver
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07391657A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Colorado Blood Cancer Institute, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05652335A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Colorado Blood Cancer Institute, Denver
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06500884A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07073547A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06768489A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07258511A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Colorado Blood Cancer Institute /ID# 279080, Denver
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07095452Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- CBCI, Colorado Blood Cancer Institute, Denver
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT04910568Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06297226A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07637578A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Denver
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07681596MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- UCHealth Poudre Valley Hospital, Fort Collins
- UCHealth Harmony, Fort Collins
- UCHealth Greeley Hospital, Greeley
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/24更新 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Penrose-Saint Francis Healthcare, Colorado Springs
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs
- Saint Francis Cancer Center, Colorado Springs
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04566328A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Colorado Blood Cancer Institute/SCRI, Denver
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/18更新 · NCT06292780AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Aurora
- Research Site, Denver
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Aurora
- Research Site, Denver
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/14更新 · NCT07764978A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Colorado Blood Cancer Institute /ID# 273129, Denver
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/21更新 · NCT06892522Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Colorado Blood Cancer Institute, Denver
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/16更新 · NCT05469893A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Rocky Mountain Cancer Centers - Aurora /ID# 268574, Aurora
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/13更新 · NCT05650632Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- UCHealth Poudre Valley Hospital, Fort Collins
- UCHealth Harmony, Fort Collins
- UCHealth Greeley Hospital, Greeley
- 他3件
被験者募集中第4相
18歳以上 · 全性別 · 2026/07/01更新 · NCT06057402Integrated Cancer Repository for Cancer Research
- Advent Health, Greenwood Village
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Rocky Mountain Regional VA Medical Center, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs
- 他6件
被験者募集中第3相
全年齢 · 全性別 · 2026/06/10更新 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Colorado Hospital, Aurora
- Colorado Blood Cancer Institute, Denver
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/04更新 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
被験者募集中第2相
19歳以上 · 全性別 · 2026/06/04更新 · NCT06974786A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- Colorado Blood Cancer Institute/SCRI, Denver
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/13更新 · NCT05828511Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute /ID# 273751, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/12更新 · NCT06896916A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Aurora
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/22更新 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/22更新 · NCT05972135Survivors Uniting for Remote Guided Exercise
- Human Performance Clinical Research Lab, Fort Collins
被験者募集中
18歳以上 · 全性別 · 2026/03/31更新 · NCT07290309A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Colorado Blood Cancer Institute, Denver
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/18更新 · NCT06153251CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- CU Anschutz Medical Campus, Anshutz Cancer Pavillion, Aurora
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/25更新 · NCT05722418ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。